Showing 601 - 620 results of 26,827 for search '(( 50 ((mg decrease) OR (a decrease)) ) OR ( 50 ((ns decrease) OR (nn decrease)) ))', query time: 0.70s Refine Results
  1. 601

    FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells. by Laura L. Stafman (6577184)

    Published 2019
    “…<p>(A) Following 24 hours of treatment with FTY720, the viability of HuH6 cells measured using the alamarBlue cell viability assay was significantly decreased (LD<sub>50</sub> = 8.4 μM, p ≤ 0.05). …”
  2. 602

    MTT assay shows that the cells exposed to periostin siRNA showed a significant decrease in IC50 among the DDP, EPI, and DTX compared with the control siRNA group (control group) (<i>P</i><0.01). by Dongyang Xu (303547)

    Published 2013
    “…<p>MTT assay shows that the cells exposed to periostin siRNA showed a significant decrease in IC50 among the DDP, EPI, and DTX compared with the control siRNA group (control group) (<i>P</i><0.01).…”
  3. 603
  4. 604
  5. 605

    TEMPO-Oxidized Microcrystalline Cellulose for Rapid Adsorption of Ammonium by Jia Hui Ong (12085606)

    Published 2022
    “…Despite a slight decrease in adsorption performance, the material can be regenerated and applied in a real water sample. …”
  6. 606

    Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  7. 607

    Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  8. 608
  9. 609
  10. 610
  11. 611

    A Functional 12T-Insertion Polymorphism in the <i>ATP1A1</i> Promoter Confers Decreased Susceptibility to Hypertension in a Male Sardinian Population by Victoria L. Herrera (383897)

    Published 2015
    “…The <i>ATP1A1</i> promoter containing the 12T-insertion exhibited decreased transcriptional activity in in vitro reporter-assay systems, indicating decreased α1Na,K-ATPase expression with the 12T-insertion, compared with the 12T-deletion <i>ATP1A1</i> promoter. …”
  12. 612

    Fig 1 - by Ibrahim T. El-Ratel (16535296)

    Published 2023
    Subjects:
  13. 613
  14. 614
  15. 615
  16. 616
  17. 617
  18. 618
  19. 619
  20. 620